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Background: The aim of this study was the rapid identification of blaKPC gene in 38 Klebsiella pneumoniae clinical
isolates with reduced susceptibility to carbapenems. The modified Hodge Test (MHT) was carried out to
phenotypically determine whether resistance to carbapenems was mediated by a carbapenemase. The detection of
the blaKPC gene was performed by real-time acid nucleic sequence-based amplification (NASBA
TM), specifically
designed for the detection of KPC RNA target.
Results: Thirty-two/38 isolates evaluated by MHT showed the production of carbapenemases, while all the strains
exhibited the production of KPC by inhibition test with phenylboronic acid (the combined disk test with IPM/IPM
plus phenylboronic acid). The detection of blaKPC gene by Nuclisens EasyQ KPC yielded positive results in 38/38
(100%) strains. The presence of blaKPC gene was confirmed in all K. pneumoniae isolates when tested by the gold
standard PCR assay.
Conclusions: In consideration of the serious challenge represented by infections due to K. pneumoniae it appears
necessary the rapid identification of carbapenemases in clinical settings as it is made possible by the use of
NASBATM assay.
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Over the last decade carbapenemase-producing Enterobac-
teriaceae have emerged and these multidrug-resistant
pathogens became a problem in the clinical care of patients.
Among Enterobacteriaceae, Klebsiella pneumoniae carba-
penemase (KPC)-producing strains of K. pneumoniae
broadly disseminated worldwide (Nordmann et al. 2009).
KPC is a beta-lactamase enzyme, classified as ESBLCARBA-A,
(Giske et al. 2009) encoded by blaKPC gene, that confers
resistance to all beta-lactam antibiotics including carbape-
nems. Misidentification of KPC-producing bacteria is
common with standard susceptibility testing (Nordmann
et al. 2009), whereas the presence of a KPC may cause
MIC elevations that remain within the susceptible or* Correspondence: giuseppe.miragliotta@uniba.it
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in any medium, provided the original work is pintermediate range. Therefore, although time-consuming,
phenotypic confirmation tests (i.e. modified Hodge test
(MHT) and carbapenemase inhibitor test) have been
recommended (Clinical and Laboratory Standards Institute
2009). Inappropriate treatment may be the consequence of
inaccurate detection of KPCs, resulting in compromised
patients’ outcomes (Weisenberg et al. 2009). The emer-
gence of metallo beta-lactamases (MBLs) producing
K. pneumoniae strains further suggested the need to inves-
tigate the mechanism of resistance for a more rapid infec-
tion control perspective (Vatopoulos 2008). In order to
control the spread of blaKPC –containing bacteria in hospi-
talized patients, an important role may be played by a rapid
and sensitive blaKPC diagnostic tools which help in isolating
colonized or infected patients. In this report, we evaluated
the performance of a new molecular assay (NASBATM,
NucliSens EasyQKPC, bioMérieux, France), for the rapid
detection of blaKPC gene in isolates of K. pneumoniae fromn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Surgical wards of the teaching hospital Policlinico of Bari,
Bari, Italy.
Materials and methods
Clinical isolates. A total of 38 non duplicate clinical
isolates of K. pneumoniae resistant to carbapenems
[i.e. imipenem (IPM), meropenem (MEM), ertapenem
(ERT)] were included in this study. The isolates were
collected in a period of four months (September to
December 2011) from separate patients who were hospi-
talized in the teaching hospital Policlinico of Bari, Bari,
Italy. Microorganisms were isolated from multiple infec-
tion sites, including blood (n = 10), urine (n = 11), bron-
chial aspirate (n = 10), rectal swabs (n = 3), throat swab
(n = 1), sputum (n = 2), and bile (n = 1) specimens.
K. pneumoniae (n = 4), Pseudomonas aeruginosa (n = 2),
Acinetobacter spp. (n = 2), and Escherichia coli (n = 2)
with no known resistance were included as negative
control.
Antimicrobial susceptibility determination and carbape-
nemases assays. Detailed antimicrobial susceptibility was
carried out automatically and interpreted according to
the recommendations of European Committee for Anti-
microbial Susceptibility testing (EUCAST) (Vading et al.
2011). All K. pneumoniae strains were identified as
possible KPC producers by MicroScan Walkaway System
using 43 MS GNC panels (Siemens, New York, NY) on
the basis of resistance to IPM, MEM and ERT. The
resistance level of K. pneumoniae isolates to IPM was
confirmed by Etest (bioMérieux, France) according to
the manufacturers’ instructions. All isolates were
screened for the production of carbapenemases, using
MHT which is a phenotypic test used to determine if
resistance to carbapenems is mediated by a carbapene-
mase enzyme (Carvalhaes et al. 2010). This test was
performed using both MEM and IPM 10 μg disks. The
presence of a distorted inhibition zone after overnight
incubation was interpreted as a positive test result. The
isolates were further investigated by combined disk test
with IPM and IPM plus phenylboronic acid (PBA) or
ethylenediaminetetraacetic acid (EDTA) as inhibitors of
KPC or MBLs, respectively (Tsakris et al. 2009). The
stock solution of PBA was prepared by dissolving
PBA (benzeneboronic acid; Sigma-Aldrich, Steinheim,
Germany) in dimethylsulfoxide and water at a concen-
tration of 20 mg/mL (Coudron 2005). From this solution
20 μL was dispensed onto IPM disks. The combined disk
IPM/EDTA was purchased from Biolife, Italy. Inhibition
tests were performed for the detection of ESBLs and
therefore stock solution of PBA was also dispensed onto
disks containing ceftazidime (CAZ) or cefotaxime (CTX)
with and without clavulanate (CA) at the same final
amount (i.e. 400 μg). All the antibiotic disks werecommercially available. The tests were performed by in-
oculating Mueller Hinton agar plates with the standard disk
diffusion method; an increase in the growth-inhibitory zone
around the disk containing the added beta-lactamase
inhibitor was observed. The test was considered positive for
KPC or MBLs when the growth inhibitory zone around
either the IPM/PBA or the IPM/EDTA disk was 5 mm or
greater of the growth inhibitory zone diameter around the
disk containing IPM alone. With regard to the detection of
ESBLs, when the zone diameter of either CTX-CA
or CAZ-CA disk tested in combination with PBA (CTX-
CA-PBA or CAZ-CA-PBA, respectively) was 5 mm or
greater of the zone diameter of CTX or CAZ containing
PBA (CTX-PBA or CAZ-PBA, respectively) the test was
considered positive. The presence of AmpC beta-lactamase
was phenotypically tested by determining IPM MICs in
agar with and without 200 μg/ml cloxacillin and by using
the AmpC detection Etest strips (bioMérieux, France).
Detection of blaKPC gene by molecular methods. All
K. pneumoniae isolates were also investigated by nucleic
acid sequence-based amplification, NASBATM, NucliSens
EasyQ KPC (bioMérieux, France), for the detection of
the blaKPC gene. This molecular method couples nucleic
acid sequence-based amplification (NASBA) with real-
time procedure assay. NASBA is a sensitive, isothermal,
transcription-based amplification system designed spe-
cifically for the detection of KPC RNA target in real time
mode. Nucleic acid amplification uses primers that are
specific for KPC RNA sequences and for the synthetic
KPC internal control RNA. Any KPC RNA present in
the sample is co-amplified along with the internal
control otherwise other nucleic acid sequences will not
be amplified. According to the manufacturer’s instruc-
tions, a 0.5 McFarland suspension of each isolate was
prepared from an overnight non selective culture plate
and heated at 95°C for 5 min. The reaction mixture was
prepared in the tube strip by transferring 2.5 μl of
internal control solution, 2.5 μl of heated bacterial
suspension, 10 μl of primers solution (including both
primers, molecular beacon probes and nucleotides) and
incubated for 2 minutes at 65°C and 2 minutes at 41°C.
After addition of 5 μL of enzyme mix (AMV-RT, RNase
H and T7 RNA polymerase, bovine serum albumin),
amplification was followed for 90 minutes at 41°C in
NucliSENSE EasyQ Analyzer (bioMérieux, France)
according to the assay protocol. Results were validated
for each isolate according to the amplification of the
internal control.
In order to compare the results obtained by Nuclisens
EasyQ KPC method with a gold standard molecular test all
the 38/38 isolates, along with the negative control strains,
were further investigated by PCR assay using the fol-
lowing primers: blaKPC For: TGTCACTGTATCGCCGTC;




Figure 1 Representative results of inhibition test with IPM, IPM/
PBA, and IPM/EDTA for Klebsiella pneumoniae isolates.
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denaturation step at 95°C (5 min) followed by 35 cycles at
95°C for 60 sec, 55°C for 40 sec, 72°C for 90 sec; was also
included a cycle of extension at 72°C for 10 min.
Results
All the K. pneumoniae strains exhibited the same pattern
of antibiotic susceptibility (Table 1). The isolates showed
resistance to all the antibiotics tested with the exception
of gentamycin (MIC, < 2 μg/ml), tigecycline (MIC, < 1
μg/ml), fosfomycin (MIC, < 32 μg/ml), and tetracycline
(MIC, ≤ 4 μg/ml). Carbapenems susceptibility carried
out by automated testing revealed MICs >8 μg/ml for
IPM and MEM, and >4 μg/ml for ERT, respectively.
When IPM susceptibility was determined by Etest
MIC50 and MIC90 values were >32 μg/ml (range
4 μg/ml-32 μg/ml). Thirty-two/38 (84%) strains eval-
uated by MHT showed the production of carbapene-
mase, regardless of carbapenems tested. Six/38 (16%)
strains negative to MHT had IPM MIC values
decreased (range 4 μg/ml-12 μg/ml). All the isolates
were positive for the combined disk test with PBA,
thus suggesting the production of KPC-type enzyme
(Figure 1). Figure 2 shows the increase of the inhib-
ition zone in the presence of IPM in comparison
with the inhibition zone in the presence of IPM/Table 1 Susceptibility profile of all K. pneumoniae isolates
tested by automated system against different
antimicrobial agents
Antimicrobial agents MIC (μg/ml)
Amikacin > 32 R
Amoxicillin/ Clavulanate > 16/8 R
Aztreonam > 16 R
Cefepime > 16 R
Cefotaxime > 32 R
Ceftazidime > 16 R
Cefuroxime > 16 R
Ciprofloxacin > 2 R
Ertapenem > 4 R
Fosfomycin ≤ 32 S
Gentamicin ≤ 4 S
Imipenem > 8 R
Levofloxacin > 4 R
Meropenem > 8 R
Piperacillin/Tazobactam > 64 R
Tetracycline ≤ 4 S
Tigecycline ≤ 1 S
Tobramycin > 8 R
Trimetoprim/Sulfametoxazole > 2/38 R
S, susceptible; R, Resistant.PBA. In 4/38 strains the co-production of both KPC
and MBLs was suggested by the difference of at least
7 mm between the diameters of inhibition zone of
IPM and IPM/EDTA. Since the Ampc detection was
negative in all the cases, the presence of plasmid-
mediated Ampc was excluded. The CLSI confirma-
tory test in the presence of clavulanate/PBA was
positive for CAZ and CTX, clearly indicating the co-
production of ESBLs. The detection of blaKPC gene
by Nuclisens EasyQKPC yielded positive results in
38/38 (100%) cases. All control isolates resulted
negative for either phenotypic or genotyping tests
(Table 2).
In order to confirm the presence of blaKPC gene by a
standard and well known molecular method, all the iso-
lates were further investigated by PCR assay. According
to the EasyQ KPC assay, all the strains resulted positive
by PCR, thus confirming the presence of the blaKPC
resistance determinant. Control isolates previously
resulted negative (i.e. by phenotypic or genotyping tests)
were also confirmed by PCR assay (Table 2).
Discussion
Carbapenems are beta-lactam antibiotics with broad-
spectrum antibacterial activity, often used to treat infec-
tions due to ESBL-producing Gram-negative bacteria
(Paterson and Bonomo 2005). Resistance to carbape-
nems represents a serious problem in the treatment of
such infections. In particular, KPCs enzymes are capable
of hydrolyzing all known beta-lactam antibiotics and
displaying resistance to beta-lactamase inhibitors. While
the presence of ESBLs can be masked by the expression























Figure 2 Increase in the inhibition zone diameters of IPM/PBA disks versus those of IPM for 38 Klebsiella pneumoniae isolates.
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either the hydrolytic activity of KPC or the resistance to
broad-spectrum cephalosporins (Nordmann et al. 2009).
KPC genes are carried on a variety of plasmids and may
be co-transferred with ESBL genes (Petrella et al. 2008;
Tsakris et al. 2008). Moreover, both genes are often asso-
ciated with plasmid mediated fluoroquinolone and ami-
noglycoside resistance determinants (Nordmann et al.
2009; Poirel et al. 2006). Therefore, the horizontal trans-
mission of blaKPC genes highly contributes to the
dissemination of strains resistant to several classes of
antibiotics leaving a few therapeutic choices. Over recent
years, the spread of KPC-producing bacteria created the
necessity to implement the laboratory with tests able to
promptly report any carbapenem-resistant isolate to
either the clinician for the appropriated antimicrobial
therapy or the hospital infection control team for the
appropriate contact isolation precautions. However,
detection of carbapenem-resistant organisms may be
problematic because some isolates express low levels of
resistance that may not be detected by conventional
methods (Landman et al. 2005; Anderson et al. 2007)
and results still vary among different methods (Bulik
et al. 2010). When carbapenems susceptibility was inves-
tigated by automated systems, we were precluded from
comparing the accuracy of MICs above 8 μg/ml as itTable 2 Phenotypic and genotypic detection of Klebsiella pne
Clinical isolates (No) Modified
Hodge Test
(MHT)
K. pneumoniae (38) 32/38 positive
6/38 negative
K. pneumoniae (4), P. aeruginosa (2), Acinetobacter ssp. (2),
E. coli (2) with no known resistance
10/10 negativewas done by using Etest for IPM susceptibility determi-
nation. On the other hand, susceptibility tests of carba-
penemase producing bacteria using Etest are often
difficult to interpret (Nordmann et al. 2009). Indeed,
carbapenem-resistant bacteria incorrectly identified as
carbapenem-susceptible have been reported, with the
result of inappropriate selection of therapy (Anderson
et al. 2007; Bratu et al. 2005; Tenover et al. 2006). MHT
was also evaluated for detection of KPC-mediated resist-
ance. This phenotypic test is sensitive for the detection
of carbapenemases production but does not provide
information regarding the type of enzyme involved.
False-positive results have been indeed reported for
CTX-M beta-lactamases producing strains with reduced
outer membrane permeability (Carvalhaes et al. 2010;
Pasteran et al. 2009). Some investigators have raised the
problem of difficulties in the interpretation of the clover-
leaf test for weak carbapenemase producers (Pasteran
et al. 2009). In our study 6/38 (16%) strains negative to
MHT had IPM MIC values decreased (range 4 μg/ml-
12 μg/ml). The inhibition test with PBA allowed to
detect the production of KPC, whereas EDTA positivity
suggested the co-production of MBLs. Although in our
hands the results were clear, it has been noted that the
interpretation of inhibition test may be difficult and





38/38 positive 4/38 positive 38/38 positive 38/38 positive
10/10 negative 10/10 negative 10/10 negative 10/10 negative
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detect carbapenemases important from a clinical point
of view by methods not impractical for studies involving
large sample sizes, as well as for rapid identification in
clinical settings. Molecular methods such as PCR and
real time-PCR, for the identification of blaKPC gene have
been used principally in research laboratories and refe-
rence centers (Hindiyeh et al. 2008).
Conclusions
We have herein described the performance of a nowadays
commercially available test based on real time-NASBA, for
the automated amplification detection of blaKPC gene. Our
results are consistent with those recently published which
confirm the advantages of this test (Spanu et al. 2012).
Aside from its sensitivity, it has indeed confirmed to facili-
tate results with significantly less time (4 hours) and labor,
allowing an even more rapid detection of drug-resistant
bacteria in clinical samples.
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